|
gptkbp:instanceOf
|
gptkb:drug
immunosuppressant
|
|
gptkbp:administeredBy
|
intravenous infusion
subcutaneous injection
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2005
|
|
gptkbp:ATCCode
|
L04AA24
|
|
gptkbp:bioavailability
|
100% (IV)
|
|
gptkbp:brand
|
gptkb:Orencia
|
|
gptkbp:CASNumber
|
332348-12-6
|
|
gptkbp:contains
|
gptkb:CTLA-4
IgG1 Fc region
|
|
gptkbp:contraindication
|
hypersensitivity
serious infections
|
|
gptkbp:developedBy
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:drugClass
|
immunotherapy
|
|
gptkbp:eliminatedIn
|
proteolytic degradation
|
|
gptkbp:halfLife
|
13-16 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
abatacept
|
|
gptkbp:indication
|
moderate to severe rheumatoid arthritis
polyarticular juvenile idiopathic arthritis
active psoriatic arthritis
|
|
gptkbp:isBiosimilarAvailable
|
no
|
|
gptkbp:KEGGID
|
D03136
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
selective T-cell co-stimulation modulator
|
|
gptkbp:MedlinePlusID
|
a606011
|
|
gptkbp:molecularWeight
|
92 kDa
|
|
gptkbp:notPrescribedWith
|
TNF antagonists
|
|
gptkbp:patent
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:prescribedWith
|
gptkb:methotrexate
|
|
gptkbp:PubChem_CID
|
CHEMBL1201587
9933473
DB01275
|
|
gptkbp:RxNormID
|
403947
|
|
gptkbp:sideEffect
|
nausea
headache
hypertension
infections
|
|
gptkbp:structureType
|
gptkb:protein
|
|
gptkbp:target
|
gptkb:CD80
gptkb:CD86
|
|
gptkbp:UNII
|
3KX376GY7L
|
|
gptkbp:usedFor
|
gptkb:juvenile_idiopathic_arthritis
gptkb:psoriatic_arthritis
rheumatoid arthritis
|
|
gptkbp:bfsParent
|
gptkb:CTLA-4
gptkb:L04AC02
|
|
gptkbp:bfsLayer
|
6
|